院外心脏骤停复苏成功且无ST段抬高患者的早期风险分层——TOMAHAWK风险评分
本研究为TOMAHAWK试验的预设亚组分析,在52个中心、3个国家开发并外部验证了一个用于院外心脏骤停复苏成功且复苏后心电图无ST段抬高患者的简易风险评分。评分基于5个独立预测因子(年龄≥72岁、已知糖尿病、初始心律不可电击、ROSC时间≥23分钟、入院动脉乳酸≥8 mmol/L),将患者分为低危(0-2分)、中危(3-6分)和高危(7-10分),对应30天死亡率分别为23.6%、68.8%和86.2%(p < 0.001),AUC为0.82。在COACT队列和柏林队列外部验证中,各风险组死亡率仍呈显著分层(各p < 0.001)。该评分便于日常临床实践快速计算,与死亡率强相关。
要点
- TOMAHAWK风险评分包含5个变量:年龄≥72岁、已知糖尿病、初始不可电击心律、ROSC时间≥23分钟、入院动脉乳酸≥8 mmol/L。
- 评分范围0-10分,分为低危(0-2分)、中危(3-6分)、高危(7-10分)三层。
- 开发队列中30天死亡率分别为低危23.6%、中危68.8%、高危86.2%(p < 0.001),AUC 0.82。
- 外部验证COACT队列死亡率分别为23.1%、44.8%、78.9%(各p < 0.001)。
- 外部验证柏林队列死亡率分别为20.4%、48.1%、73.3%(各p < 0.001)。
适用人群与场景
- 成年患者,院外心脏骤停复苏成功,复苏后心电图无ST段抬高。
- 开发队列来自TOMAHAWK试验;外部验证队列包括COACT试验(仅可电击心律)和德国柏林额外医院(可电击和不可电击心律)。
诊断标准与关键阈值
- TOMAHAWK风险评分:年龄≥72岁、已知糖尿病、初始心电图不可电击心律、ROSC时间≥23分钟、入院动脉乳酸≥8 mmol/L,每个变量赋1-4分,总分0-10分。
- 风险分层:低危0-2分,中危3-6分,高危7-10分。
研究设计与关键结果
- 研究类型:TOMAHAWK试验的预设亚组分析,开发并外部验证风险评分,覆盖3个国家52个中心。
- 评分开发采用后向逐步回归分析,5个变量为30天死亡的独立预测因子。
- 开发队列30天死亡率:低危23.6%,中危68.8%,高危86.2%(p < 0.001),AUC 0.82。
- 外部验证COACT队列短期死亡率:低危23.1%,中危44.8%,高危78.9%(各p < 0.001)。
- 外部验证柏林队列短期死亡率:低危20.4%,中危48.1%,高危73.3%(各p < 0.001)。
证据类型、等级与局限
- 证据类型:基于随机对照试验TOMAHAWK的预设亚组分析,并在COACT试验队列和柏林医院队列中进行外部验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为TOMAHAWK风险评分可在日常临床实践中轻松计算,并与无ST段抬高的院外心脏骤停复苏成功患者的死亡率强相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Existing scores for risk stratification after out-of-hospital cardiac arrest (OHCA) are either medically outdated, limited to registry data, small cohorts, and certain healthcare systems only, or include rather complex calculations. The objective of this study was to develop an easy-to-use risk prediction score for short-term mortality in patients with successfully resuscitated OHCA without ST-segment elevation on the post-resuscitation electrocardiogram, derived from the Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation (TOMAHAWK) trial. The risk score was externally validated in the Coronary Angiography after Cardiac Arrest Trial (COACT) cohort (shockable arrest rhythms only) and additional hospitals from Berlin, Germany (shockable and nonshockable arrest rhythms).
DESIGN: Predefined subanalysis of the TOMAHAWK trial.
SETTING: Development and external validation across 52 centers in three countries.
PATIENTS: Adult patients with successfully resuscitated OHCA and no ST-segment elevations.
INTERVENTIONS: Utilization of the TOMAHAWK risk score upon hospital admission.
MEASUREMENTS AND MAIN RESULTS: The risk score was developed using a backward stepwise regression analysis. Between one and four points were attributed to each variable in the risk score, resulting in a score with three risk categories for 30-day mortality: low (0-2), intermediate (3-6), and high (7-10). Five variables emerged as independent predictors for 30-day mortality and were used as risk score parameters: age of 72 years old or older, known diabetes, unshockable initial electrocardiogram rhythm, time until return of spontaneous circulation greater than or equal to 23 minutes, and admission arterial lactate level greater than or equal to 8 mmol/L. The 30-day mortality rates for each risk category were 23.6%, 68.8%, and 86.2%, respectively (p < 0.001) with a good discrimination at an area under the curve of 0.82. External validation in the COACT and Berlin cohorts showed short-term mortality rates of 23.1% and 20.4% (score 0-2), 44.8% and 48.1% (score 3-6), and 78.9% and 73.3% (score 7-10), respectively (each p < 0.001).
CONCLUSIONS: The TOMAHAWK risk score can be easily calculated in daily clinical practice and strongly correlated with mortality in patients with successfully resuscitated OHCA without ST-segment elevation on post-resuscitation electrocardiogram.
参考来源
- Thevathasan T, Spoormans E, Akin I, et al. Early Risk Stratification of Patients After Successfully Resuscitated Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation-The Angiography After Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation (TOMAHAWK) Risk Score. Crit Care Explor. 2025. PMID: 40042208. doi:10.1097/CCE.0000000000001221
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。